Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment

Cutting-edge assays for mirabegron and tadalafil combo therapy for benign prostatic hyperplasia; insilico kinetics approach; multi trait sustainability assessment

Abstract The combination therapy of mirabegron (MIR) and tadalafil (TAD) has gained significant attention in clinical practice for the treatment of Benign Prostatic Hyperplasia as well as overactive bladder syndrome. This study demonstrates the development and validation of two analytical methods fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara I. Aboras, Mohamed R. Abdelhakim, Hadir M. Maher, Rasha M. Youssef
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Chemistry
Subjects:
Mirabegron
Tadalafil
HPLC
Spectrophotometry
Benign prostatic hyperplasia
Sustainability
Online Access:https://doi.org/10.1186/s13065-025-01497-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items